Kymera Therapeutics
KYMR
108.35
+2.37
+2.24%
Kymera Therapeutics
US · KYMR
#1580 by market cap
Listed 2020
108.35
+2.37
+2.24%
Live - 5344 symbols - heartbeat 197s ago
· 2026-10-08 04:01
Pre-market
108.35
0.00%
After-hours
106.00
-2.17%
- Market cap
- 9.01B
- P/E (TTM)i
- -33.34
- P/Bi
- 5.97
- EPSi
- -3.69
- Div yieldi
- 0.00%
- 52W posi
- 71%
Reader sentiment
Are you bullish or bearish on KYMR?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions increased by 4 in the most recent period (2026/Q3).
- Total institutional ownership rose 1.8 percentage points.
Institutional ownership
- Held by institutions
- 112.43% +1.82pp
- Institutions
- 347 +4
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund69.16%
Hedge Fund30.44%
VC/PE Fund8.67%
Public Company2.19%
Individual/Insider1.18%
Sovereign Wealth Fund0.92%
Private Company0.60%
Government Pension Fund0.26%
Insurance Company0.16%
Top holders as of 2026-06-30
FMR
14.85% · 12.35M sh
T. Rowe Price Group, Inc.
10.67% · 8.87M sh
Baker Bros. Advisors LP
10.41% · 8.66M sh
Avoro Capital Advisors LLC
8.99% · 7.47M sh
BlackRock
6.66% · 5.54M sh
BVF Partners L.P.
4.66% · 3.87M sh
Wellington Management Group
4.42% · 3.68M sh
Vanguard Capital Management, LLC
4.07% · 3.38M sh
Vanguard Portfolio Management, LLC
3.60% · 2.99M sh
Artal Group S.A.
3.53% · 2.94M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 14 buys · 36 sells
| Name | Role | Stake |
|---|---|---|
| Baker Bros. Advisors LP | -- | 10.41% |
| Nello Mainolfi | Chief Executive Officer | 0.80% |
| Bruce Jacobs | Chief Financial Officer | 0.24% |
| Jared Gollob | Chief Medical Officer | 0.09% |
| Brian Adams | Chief Legal Officer | 0.03% |
| Ellen Chiniara | Chief Legal Officer | 0.02% |
| Jeremy Chadwick | Chief Operating Officer | 0.00% |
| Pamela Esposito | Independent Director | 0.00% |
| Noah Goodman | Chief Business Officer | 0.00% |
| Atlas Venture Advisors, Inc. | -- | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-30 | Nello Mainolfi | Chief Executive Officer | Derivative Exercise and Sale | -30,000 | $2.08–116.12 |
| 2026-09-03 | Brian Adams | Chief Legal Officer | Open Market Disposition | -6,371 | $115.55–117.57 |
| 2026-09-01 | Jeremy Chadwick | Chief Operating Officer | Intent to Sell (Form 144) | -10,879 | $119.05 |
| 2026-07-26 | Terence Rooney | Chief Medical Officer | Other Acquisition | +38,000 | -- |
| 2026-07-26 | Terence Rooney | Chief Medical Officer | Other Derivative Acquisition | +76,000 | $110.05 |
| 2026-07-06 | Nello Mainolfi | Chief Executive Officer | Derivative Exercise and Sale | -50,000 | $2.08–119.00 |
| 2026-06-30 | Nello Mainolfi | Chief Executive Officer | Derivative Exercise and Sale | -80,000 | $2.08–116.56 |
| 2026-06-30 | Noah Goodman | Chief Business Officer | Automatic Disposition | -3,389 | $114.29 |
| 2026-06-29 | Bruce Jacobs | Chief Financial Officer | Automatic Disposition | -15,731 | $115.82–117.70 |
| 2026-06-29 | Bruce Jacobs | Chief Financial Officer | Derivative Exercise and Sale | -61,378 | $5.33–115.82 |
| 2026-06-25 | BVF Partners L.P. | -- | Private Disposition | -1,630,658 | $106.50 |
| 2026-06-24 | Noah Goodman | Chief Business Officer | Derivative Exercise and Sale | -5,000 | $21.05–119.00 |
| 2026-06-23 | John Michael Maraganore | Independent Director | Other Derivative Acquisition | +6,068 | $99.87 |
| 2026-06-23 | Felix Baker | Lead Independent Director | Other Derivative Acquisition | +12,136 | $99.87 |
| 2026-06-23 | BVF Partners L.P. | -- | Other Derivative Acquisition | +6,068 | $99.87 |
| 2026-06-23 | Elena Ridloff | Independent Director | Other Derivative Acquisition | +6,068 | $99.87 |
| 2026-06-23 | Bruce Booth | Chairperson | Other Derivative Acquisition | +6,068 | $99.87 |
| 2026-06-23 | Jeffrey Albers | Independent Director | Other Derivative Acquisition | +6,068 | $99.87 |
| 2026-06-23 | Pamela Esposito | Independent Director | Other Derivative Acquisition | +6,068 | $99.87 |
| 2026-06-23 | Victor Sandor | Director | Other Derivative Acquisition | +6,068 | $99.87 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 04:01:21 · For reference only, not investment advice and not tailored to your situation.